Drug Landscape ›
Levetiracetam 250mg ›
Regulatory · United States
Marketing authorisation
FDA
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
Window: 20 April 2025 – 20 April 2026
Total reports: 18
Most-reported reactions
Seizure — 4 reports (22.22%) Electrocardiogram Qt Prolonged — 2 reports (11.11%) Personality Change — 2 reports (11.11%) Product Substitution Issue — 2 reports (11.11%) Suicidal Ideation — 2 reports (11.11%) Torsade De Pointes — 2 reports (11.11%) Acute Kidney Injury — 1 report (5.56%) Agitation — 1 report (5.56%) Anger — 1 report (5.56%) Anxiety — 1 report (5.56%)
Source database →
Levetiracetam 250mg in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Frequently asked questions
Is Levetiracetam 250mg approved in United States?
Yes. FDA has authorised it.
Who is the marketing authorisation holder for Levetiracetam 250mg in United States?
Johns Hopkins University is the originator. The local marketing authorisation holder may differ — check the official source linked above.